MA-based biotech company Heranova Lifesciences $13.5M in seed+ funding. Sinovation Ventures, Emerging Technology Partners, Pivotal bioVenture Partners China, and Triwise Capital were among the backers.

The funds will be utilised by the company to advance two novel (non-hormonal, non-antibiotic) therapeutic programmes for endometriosis and bacterial vaginosis, as well as to begin a series of non-invasive endometriosis tests.

Read also – ME-based Biochar Producer Standard Biocarbon Secures $5M in Funding

Heranova Lifesciences, a biotech company, is led by Chief Diagnostic Medical Officer Dr. Farideh Bischoff and CEO Dr. Jonathan Y. Zhao. The company’s exclusive focus is on developing integrated care solutions for women’s health.

By offering diagnostics, medications, and devices that are both internally developed and externally partnered with, they hope to address needs in women’s healthcare. The business already has operations in Asia and the United States.

Read also – CA-based Hyperlink Ventures Secures it’s First fund at $32M

About Heranova Lifesciences

Heranova is a global women’s health company that focuses on treating women’s unmet medical needs. Women’s healthcare is at present in far worse shape than it should be, with many medical needs going unmet. They are dedicated to meeting these unmet healthcare needs for women at every stage of their lives, including menopause, pregnancy, and reproductive health.

Read also – TX-based Cart.com Secures $30M Growth Funding